64 results
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
and reimbursement of certain out-of-pocket expenses. As additional compensation we issued to WallachBeth Capital LLC a warrant (the “Placement Agent
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
for the offering and received a cash fee of 9.0% of the aggregate gross proceeds paid to us for the securities sold in the transactions and reimbursement
8-K
EX-99.1
BIAF
BioAffinity Technologies Inc
15 May 24
Results of Operations and Financial Condition
6:07pm
reimbursement for CyPath® Lung became effective on January 1, 2024.
More than 547% annualized growth rate for CyPath® Lung orders in first four months
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
result in significant liability.
Our ability to obtain adequate reimbursement from third-party payors may impact our revenues.
Our employees, consultants … and third-party medical insurance and adequate reimbursement for our diagnostic tests or therapeutic products;
any restrictions on the use of our
POS AM
lzp0a4 r932v
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
8-K
EX-1.1
kpy1x 06ikiyu
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
9weemspy
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-10.1
sd0av7jvu
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
424B5
vlmf6e4eg
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
vop8bq22v 4t22
7 Mar 24
Prospectus supplement for primary offering
9:57pm
8-K
EX-99.1
4z1 r8a80mp9898
5 Mar 24
Increasing physician interest, newly approved reimbursement code driving growth
5:26pm
8-K
3vo s7bd24fkcu
30 Nov 23
Regulation FD Disclosure
9:20am
8-K
EX-99.1
yqetq hh2
30 Nov 23
Regulation FD Disclosure
9:20am
424B5
f83s3y8t 3vq
28 Nov 23
Prospectus supplement for primary offering
4:00pm